| Not Yet Recruiting | A Phase I Study of YK012 in Primary Membranous Nephropathy NCT07234474 | Excyte Biopharma Ltd | Phase 1 |
| Recruiting | Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, NCT07289763 | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 2 |
| Withdrawn | REmission in Membranous Nephropathy International Trial (REMIT) NCT06120673 | The University of Queensland | Phase 3 |
| Recruiting | A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous NCT07204275 | Vertex Pharmaceuticals Incorporated | Phase 2 / Phase 3 |
| Recruiting | Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN) NCT07157787 | Alexion Pharmaceuticals, Inc. | Phase 2 |
| Recruiting | A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy NCT07096843 | Climb Bio, Inc. | Phase 2 |
| Not Yet Recruiting | A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous Nephropathy NCT07029139 | Shanghai JMT-Bio Inc. | Phase 2 |
| Recruiting | A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous NCT06962800 | Biogen | Phase 3 |
| Recruiting | Study of YK012 in Primary Membranous Nephropathy NCT06982729 | Excyte Biopharma Ltd | Phase 1 |
| Active Not Recruiting | A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy NCT06642909 | BioRay Pharmaceutical Co., Ltd. | Phase 2 |
| Recruiting | A Real World Study About PMN NCT06893328 | Wei Chen | — |
| Recruiting | OBINOTUZUMAB Versus Cyclophosphamide + Glucocorticoids in Primary Membranous Nephropathy(Blossom Study) NCT06781944 | Huashan Hospital | Phase 3 |
| Not Yet Recruiting | The Efficacy and Safety of Treatment With Telitacicept in Primary Membranous Nephropathy NCT06614985 | Renmin Hospital of Wuhan University | Phase 2 |
| Recruiting | Efficacy and Safety of Finerenone in Patients With Primary Membranous Nephropathy NCT06573411 | First Affiliated Hospital, Sun Yat-Sen University | Phase 4 |
| Recruiting | A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy. NCT06470191 | Shanghai Jiaolian Drug Research and Development Co., Ltd | Phase 2 / Phase 3 |
| Recruiting | Study of WAL0921 in Patients With Glomerular Kidney Diseases NCT06466135 | Walden Biosciences | Phase 2 |
| Recruiting | A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1) NCT06557265 | Nkarta, Inc. | Phase 1 / Phase 2 |
| Recruiting | Clinical Study of Rituximab Combined With Corticosteroids or Rituximab Monotherapy in the Treatment of Primary NCT05514015 | First Affiliated Hospital, Sun Yat-Sen University | Phase 4 |
| Active Not Recruiting | A Phase Ⅲ Clinical Study of MIL62 in Primary Membranous Nephropathy NCT05862233 | Beijing Mabworks Biotech Co., Ltd. | Phase 3 |
| Recruiting | Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001 NCT05800873 | Everest Medicines (China) Co.,Ltd. | Phase 1 |
| Active Not Recruiting | A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy NCT05707377 | BeOne Medicines | Phase 2 / Phase 3 |
| Recruiting | A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy NCT05696613 | Cerium Pharmaceuticals, Inc. | Phase 3 |
| Recruiting | A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Sub NCT05668403 | Shanghai Jiaolian Drug Research and Development Co., Ltd | Phase 1 |
| Completed | A Phase Ib/ Ⅱ Clinical Study of MIL62 in Primary Membranous Nephropathy NCT05398653 | Beijing Mabworks Biotech Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | Evaluate the Efficacy and Safety of SHR1459 Tablets in Patients With Primary Membranous Nephropathy NCT05136456 | Reistone Biopharma Company Limited | Phase 2 |
| Active Not Recruiting | A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy NCT04629248 | Hoffmann-La Roche | Phase 3 |
| Active Not Recruiting | Optimization of a Decision Formula for Optimal Timing of Immunosuppressive Therapy Initiation in Primary Membr NCT06924476 | Yipeng Liu | — |